These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 32028805)
21. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy. Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609 [TBL] [Abstract][Full Text] [Related]
22. Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery. Park JH; Cho HJ; Yoon HY; Yoon IS; Ko SH; Shim JS; Cho JH; Park JH; Kim K; Kwon IC; Kim DD J Control Release; 2014 Jan; 174():98-108. PubMed ID: 24280260 [TBL] [Abstract][Full Text] [Related]
23. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy. Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789 [TBL] [Abstract][Full Text] [Related]
24. Comparison of hyaluronic acid-based micelles and polyethylene glycol-based micelles on reversal of multidrug resistance and enhanced anticancer efficacy in vitro and in vivo. Wang J; Li Y; Wang L; Wang X; Tu P Drug Deliv; 2018 Nov; 25(1):330-340. PubMed ID: 29350064 [TBL] [Abstract][Full Text] [Related]
25. Multi-layered cellulose nanocrystal system for CD44 receptor-positive tumor-targeted anticancer drug delivery. Seo JH; Lee SY; Hwang C; Yang M; Lee J; Lee SH; Cho HJ Int J Biol Macromol; 2020 Nov; 162():798-809. PubMed ID: 32585268 [TBL] [Abstract][Full Text] [Related]
26. Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug. Ling L; Ismail M; Du Y; Yao C; Li X Int J Pharm; 2019 Apr; 560():246-260. PubMed ID: 30769133 [TBL] [Abstract][Full Text] [Related]
27. Engineering of Bone- and CD44-Dual-Targeting Redox-Sensitive Liposomes for the Treatment of Orthotopic Osteosarcoma. Feng S; Wu ZX; Zhao Z; Liu J; Sun K; Guo C; Wang H; Wu Z ACS Appl Mater Interfaces; 2019 Feb; 11(7):7357-7368. PubMed ID: 30682240 [TBL] [Abstract][Full Text] [Related]
28. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer. Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132 [TBL] [Abstract][Full Text] [Related]
29. Robust, tumor-homing and redox-sensitive polymersomal doxorubicin: A superior alternative to Doxil and Caelyx? Zou Y; Meng F; Deng C; Zhong Z J Control Release; 2016 Oct; 239():149-58. PubMed ID: 27569664 [TBL] [Abstract][Full Text] [Related]
30. Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo. Jian YS; Chen CW; Lin CA; Yu HP; Lin HY; Liao MY; Wu SH; Lin YF; Lai PS Int J Nanomedicine; 2017; 12():2315-2333. PubMed ID: 28392690 [TBL] [Abstract][Full Text] [Related]
31. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin. Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474 [TBL] [Abstract][Full Text] [Related]
32. Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo. Qiu M; Sun H; Meng F; Cheng R; Zhang J; Deng C; Zhong Z J Control Release; 2018 Feb; 272():107-113. PubMed ID: 29355618 [TBL] [Abstract][Full Text] [Related]
33. Integrin α Zhou B; Li M; Xu X; Yang L; Ye M; Chen Y; Peng J; Xiao L; Wang L; Huang S; Zhang L; Lin Q; Zhang Z Mol Pharm; 2021 Jul; 18(7):2634-2646. PubMed ID: 34134485 [TBL] [Abstract][Full Text] [Related]
34. Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin. Cho HJ; Yoon IS; Yoon HY; Koo H; Jin YJ; Ko SH; Shim JS; Kim K; Kwon IC; Kim DD Biomaterials; 2012 Feb; 33(4):1190-200. PubMed ID: 22074664 [TBL] [Abstract][Full Text] [Related]
35. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy. Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949 [TBL] [Abstract][Full Text] [Related]
36. Dual-effect liposomes encapsulated with doxorubicin and chlorin e6 augment the therapeutic effect of tumor treatment. Peng PC; Hong RL; Tsai YJ; Li PT; Tsai T; Chen CT Lasers Surg Med; 2015 Jan; 47(1):77-87. PubMed ID: 25559348 [TBL] [Abstract][Full Text] [Related]
37. ROS-responsive liposomes with NIR light-triggered doxorubicin release for combinatorial therapy of breast cancer. Yi H; Lu W; Liu F; Zhang G; Xie F; Liu W; Wang L; Zhou W; Cheng Z J Nanobiotechnology; 2021 May; 19(1):134. PubMed ID: 33975609 [TBL] [Abstract][Full Text] [Related]
38. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation. Han X; Li Z; Sun J; Luo C; Li L; Liu Y; Du Y; Qiu S; Ai X; Wu C; Lian H; He Z J Control Release; 2015 Jan; 197():29-40. PubMed ID: 25449802 [TBL] [Abstract][Full Text] [Related]
39. Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes. Qhattal HS; Hye T; Alali A; Liu X ACS Nano; 2014 Jun; 8(6):5423-40. PubMed ID: 24806526 [TBL] [Abstract][Full Text] [Related]
40. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Eliaz RE; Szoka FC Cancer Res; 2001 Mar; 61(6):2592-601. PubMed ID: 11289136 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]